Neutrophil dysplasia characterised by a pseudo-Pelger-Huet anomaly occurring with the use of mycophenolate mofetil and ganciclovir following renal transplantation: a report of five cases
- 1 January 2002
- Vol. 34 (3) , 263-266
- https://doi.org/10.1080/0031302022013136
Abstract
The pseudo-Pelger–Huet (PH) anomaly has been associated with a variety of primary haematological disorders, infections and drugs. Recently, the development of dysgranulopoiesis characterised by a pseudo-PH anomaly has been reported in two patients with the use of mycophe-nolate mofetil (MMF) in the setting of heart and/or lung transplantation. We present a further five cases of MMF-related dysgranulopoiesis characterised by a pseudo-PH anomaly occurring after renal transplantation. All patients were receiving standard immunosup-pression protocols for renal transplantation, including a combination of MMF, steroids and either cyclosporin or tacrolimus. Oral ganciclovir was also used for cytomegalo-virus prophylaxis in each case. Development of dysplastic granulopoiesis occurred a median of 96 days (range 66–196 days) after transplantation. Moderate or severe neutropaenia (< 1.0 × 109/l) developed in three cases, and appeared to be directly correlated with the percentage of circulating neutrophils present with dysplastic morphology. Resolution of dysgranu-lopoiesis occurred in all cases only after dose reduction and/ or cessation of both MMF and ganciclovir. In our series, the observed dysplastic granulo-poiesis appeared related to the combination of MMF and ganciclovir, rather than MMF alone. Further study is required to determine the exact incidence and pathogenesis of this pattern of bone marrow toxicity.Keywords
This publication has 9 references indexed in Scilit:
- Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patientsClinical Biochemistry, 2001
- NEUTROPHIL DYSPLASIA CAUSED BY MYCOPHENOLATE MOFETILTransplantation, 2000
- Pharmacokinetics of Mycophenolic Acid in Renal InsufficiencyTherapeutic Drug Monitoring, 2000
- Pharmacokinetic and Metabolic Investigations of Mycophenolic Acid in Pediatric Patients After Renal Transplantation: Implications for Therapeutic Drug MonitoringTherapeutic Drug Monitoring, 2000
- Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoringThe Journal of Heart and Lung Transplantation, 1999
- Association of acquired Pelger‐Huet anomaly with taxoid therapyBritish Journal of Haematology, 1996
- Mycophenolate Mofetil: A Report of the Consensus PanelTherapeutic Drug Monitoring, 1995
- Severe Hematologic Toxicity of Valproic AcidJournal of Pediatric Hematology/Oncology, 1990
- Reversible Pseudo-Pelger Anomaly Related to Sulfisoxazole TherapyNew England Journal of Medicine, 1967